Current and Novel Treatments for Ulcerative Colitis

Tran, Cuong; Katsikeros, Rosa; Abimosleh, Suzanne M.

doi:10.5772/25592

Cited by 1 publication

(2 citation statements)

References 200 publications

(217 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The dextran sulphate sodium (DSS) model of experimental colitis is one of the most widely utilised animal models of inflammatory bowel disease (Tran et al 2012 ). Oral consumption of DSS results in histopathological features resembling the damage manifest in human ulcerative colitis patients (preferentially-affecting the distal colon) and elicits an inflammatory response consistent with human inflammatory bowel disease.…”

Section: Introductionmentioning

confidence: 99%

“…Oral consumption of DSS results in histopathological features resembling the damage manifest in human ulcerative colitis patients (preferentially-affecting the distal colon) and elicits an inflammatory response consistent with human inflammatory bowel disease. DSS administration also produces overt signs of ulcerative colitis disease activity including rectal bleeding, weight loss and diarrhea (Tran et al 2012 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Emu Oil and zinc monoglycerolate independently reduce disease severity in a rat model of ulcerative colitis

Mashtoub

Howarth

2023

Biometals

View full text Add to dashboard Cite

Ulcerative colitis is characterized by colonic inflammation. Previously, Emu Oil protected the intestine against experimentally-induced inflammatory intestinal disorders. Zinc monoglycerolate (ZMG) polymer, formed by heating zinc oxide with glycerol, demonstrated anti-inflammatory and wound healing properties. We aimed to determine whether ZMG, alone or in combination with Emu Oil, could reduce acute colitis severity in rats. Male Sprague Dawley rats (n = 8/group) were orally-administered either vehicle, ZMG, Emu Oil (EO) or ZMG combined with EO (ZMG/EO) daily. Rats were provided ad libitum access to drinking water (Groups 1–4) or dextran sulphate sodium (DSS; 2%w/v; Groups 5–8) throughout the trial (days 0–5) before euthanasia on day 6. Disease activity index, crypt depth, degranulated mast cells (DMCs) and myeloperoxidase (MPO) activity were assessed. p < 0.05 was considered significant. DSS increased disease severity (days 3–6) compared to normal controls (p < 0.05). Importantly, in DSS-administered rats, ZMG/EO (day 3) and ZMG (day 6) reduced disease activity index compared to controls (p < 0.05). Following DSS consumption, distal colonic crypts lengthened (p < 0.01), occurring to a greater extent with EO compared to ZMG and ZMG/EO (p < 0.001). DSS increased colonic DMC numbers compared to normal controls (p < 0.001); an effect decreased only by EO (p < 0.05). Colonic MPO activity increased following DSS consumption (p < 0.05); notably, ZMG, EO and ZMG/EO treatments decreased MPO activity compared to DSS controls (p < 0.001). EO, ZMG and ZMG/EO did not impact any parameter in normal animals. Emu Oil and ZMG independently decreased selected indicators of colitic disease severity in rats; however, the combination did not reveal any additional benefit.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%